As Big Pharma Eye Big Buyouts In India, Merck KGaA Goes With Bangalore Genei To Sharpen Edge In Biologicals
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Away from the high decibel market speculation about moves made by Big Pharma to acquire large-sized companies in India, Darmstadt, Germany-headquartered Merck KGaA quietly picked up a little known molecular biology company called Bangalore Genei, which it claimed will help it "become one of the leading bioscience companies in India.
You may also be interested in...
Merck KGaA Establishes New Beijing-based R&D Site To Drive Asia Research
HONG KONG - German conglomerate Merck KGaA has launched a new research and development hub in Beijing as it seeks to satisfy growing demand for pharmaceutical products in China and Asia
Merck KGaA Establishes New Beijing-based R&D Site To Drive Asia Research
HONG KONG - German conglomerate Merck KGaA has launched a new research and development hub in Beijing as it seeks to satisfy growing demand for pharmaceutical products in China and Asia
Dealmaker Breaks Down The Daiichi Sankyo-Ranbaxy Deal: PharmAsia News Spotlight
Japan health care reforms enacted in April aimed at increasing the use of generics helped set the stage for the watershed deal between Daiichi Sankyo and Ranbaxy, and will have major implications for Indian generics companies, according to Mehta Partners, the Indian firm that brokered the deal on behalf of Daiichi